Figure 4.

Comparative in vitro efficacy of N- and C-terminal HSA fusion of CSL040.A, schematic representation of CSL040 and N-terminal and C-terminal fusions of CSL040 with human serum albumin (HSA). These constructs, as well as HSA alone, were comparatively assessed for in vitro inhibitory activity using (B) CH50 classical pathway hemolytic and (C) ApH50 alternative pathway hemolytic activity. Data points show the mean (±SD) activity (%) for each CR1 variant concentration (nM) tested. IC₅₀ values calculated from these data are shown in Table 3. CR1, complement receptor 1.